Novel agents for the treatment of HIV-2 infection

K. Peterson, S. Rowland-Jones

    Research output: Contribution to journalA1: Web of Science-articlepeer-review


    Many of the antiretrovirals used against HIV-1 are either ineffective or less effective in HIV-2 infection. There is in vitro evidence of the potency of maraviroc and several investigational agents against HIV-2. We conclude that, whilst specific boosted protease inhibitors combined with nucleoside analogues should still be considered the mainstays of HIV-2 treatment, maraviroc, T-1249, TAK-779 and AMD3100, as well as raltegravir, could contribute to regimens for treatment-experienced individuals. Factors bearing on the use and timing of these alternative agents are discussed.
    Original languageEnglish
    JournalAntiviral Therapy
    Issue number3
    Pages (from-to)435-438
    Number of pages4
    Publication statusPublished - 2012


    • Viral diseases
    • HIV-1
    • HIV-2
    • HAART
    • Antiretrovirals
    • Effectiveness
    • In vitro
    • Maraviroc
    • Raltegravir
    • Use
    • Timing
    • Drug development


    Dive into the research topics of 'Novel agents for the treatment of HIV-2 infection'. Together they form a unique fingerprint.

    Cite this